Neuralstem in the News
Neuralstem doses ischemic stroke patient with stem cells directly into the brain
“It is a crucial step forward for the company and the field at large, since optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord.” - Neuralstem's Chairman and CSO, Karl Johe, PhD, quoted in BioWorld's article on the ongoing NSI-566/ischemic stroke trial in Beijing.
Stem cell trial seeks longer lives for victims of deadly ALS
NSI-566/ALS Emory University Site Principal Investigator, Jonathan D. Glass, M.D., and Phase II patient, April Moundzouris, are featured in this video news story by Reuters’ Ben Gruber. Dr. Glass notes that Neuralstem’s cell therapy and the trial investigators are working towards “chang(ing) the slope” of ALS to “become a chronic disease, as opposed to a terminal disease.”
Neuralstem: Sizing Up Potential Key Events of 2014
Former biotech/pharma analyst and former Director of Research at Smith Barney and Hambrecht and Quist, Larry Smith, analyzes the progress and potential key events in the year ahead for Neuralstem’s lead cell therapy product, NSI-566, and lead small molecule compound, NSI-189, in this expansive article.
Neuralstem’s $19.6M offering takes ALS bid through phase II
In a front-page feature story, BioWorld Today’s Randy Osborne talks to Neuralstem’s President and CEO, Richard Garr, about the recent financing announcement and how, upon expected closing, it will impact current and upcoming clinical trials, including NSI-566/ALS Phase II, NSI-189/MDD
Phase II filing, and FDA-approved NSI-566/cSCI Phase I. The article also explores the company’s novel approach to cell therapy and the mechanisms of action by NSI-566 for different indications, such as building new circuitry to “bridge the gap” in spinal cord injury.
A Closer Look At Neuralstem’s ALS Treatment
Science and technology writer John Farrell explores the business and science sides of Neuralstem’s NSI-566, currently in an ongoing Phase II ALS trial. Neuralstem’s President and CEO, Richard Garr, is quoted extensively on the differentiation and commercialization aspects of the proprietary neural stem cell technology, and gives a forward-looking view of both the ALS trial, and additional planned NSI-566 trials, in this “Pharma & Healthcare” business feature.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.